NCT02998996 - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

June 1, 2017

Study Completion Date

June 1, 2017

Conditions

Influenza, Human

Interventions

BIOLOGICAL

15 µg HA/strain and 1% Endocine™

intranasal administration

BIOLOGICAL

15 µg HA/strain and 2% Endocine™

intranasal administration

BIOLOGICAL

15 µg HA/strain

intranasal administration

BIOLOGICAL

intramuscular comparator

intramuscular administration

BIOLOGICAL

intranasal comparator

intranasal administration

BIOLOGICAL

Placebo, Saline

intranasal administration

Trial Locations (2)

Site 2, Linköping

Site 1, Uppsala